Risk of severe hypocalcaemia with denosumab (Prolia): USFDA Drug safety communication

USFDA released a recent safety update for the denosumab Denosumab is a human monoclonal antibody which helps in preventing breaking down of bone cells (osteoclasts) from bone by inhibiting the receptors named – RANK (receptor activator of nuclear factor kappa beta) in the body.┬áThis medicine is intended for the treatment of following medical conditions: Osteoporosis

error: Content is protected !!